Evaluation of the myo-inositol-monacolin K association on hyperandrogenism and on the lipidic metabolism parameters in PCOS women;Valutazionedell'associazione myo-inositolo-monacolina K sull'iperandrogenismo e sui parametri del metabolismo lipidico in donne con PCOS

Minerva Ginecologica

Volumn 65, Issue 1, 2013, Pages 89-97

  Musacchio, M C ^a   Cappelli, V ^a   Di Sabatino, A ^a   Morgante, G ^a   De Leo, V ^a  

^a UNIVERSITY OF SIENA   (Italy)

Author keywords

Cholesterol; Hyperandrogenism; Insulin resistance; Lipids; Monacolin K; Myo inositol; Polycistic ovary styndrome

Indexed keywords

INOSITOL; MEVINOLIN;

DRUG EFFECT; DRUG EFFICACY; HIRSUTISM; HUMAN; HYPERANDROGENISM; INSULIN RESISTANCE; LIPID METABOLISM; MENSTRUAL IRREGULARITY; MONOTHERAPY; OVARY POLYCYSTIC DISEASE; REVIEW; ADULT; ARTICLE; DRUG COMBINATION; FEMALE; METABOLISM;

ADULT; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYPERANDROGENISM; INOSITOL; LIPID METABOLISM; LOVASTATIN; POLYCYSTIC OVARY SYNDROME; YOUNG ADULT;

MLCS; MLOWN;

EID: 84876532909     PISSN: 00264784     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (23)

1. Franks S, McCarthy MI, Hardy K. Development of polycystic ovary syndrome: involvement of genetic and environmental factors. Int J Androl 2006;29:278-85.
2. De Leo V, Musacchio MC, Palermo V, Di Sabatino A, Morgante G, Petraglia F. Polycystic ovary syndrome and metabolic comorbidities: therapeutic options. Drugs Today (Barc) 2009;45:763-75.
3. De Leo V, La Marca A, Petraglia F. Insuline lowering agents in the management of PCOS. Endocr Rev 2003;24:633-67. (Pubitemid 37330585)
4. De Leo V, La Marca A, Ditto A, Morgante G, Cianci A. Effects of metformin on gonadotropin-induced ovulation in women with PCOS. Fertil Steril 1999;72:282-5. (Pubitemid 29364624)
5. Nestler E, Jakubowicz DJ, Reamer P, Gunn RD, Allan G. Ovulatory and metabolic effects of dchiro-inositol in the polycystic ovary syndrome. N Engl JMed 1999;340:1314-20. (Pubitemid 29196593)
6. Larner J 1994 Multiple pathways in insulin signalling: fitting the covalent and allosteric puzzle pieces together. Endocr J 2:167-71. (Pubitemid 2055805)
7. Papaleo E, Unfer V, Baillargeon JP, Chiu TT. Contribution of myo-inositol to reproduction. Eur J Obstet Gynecol Reprod Biol 2009;147:120-3.
8. Nestler E, Jakubowicz DJ, Reamer P, Gunn RD, Allan G. Ovulatory and metabolic effects of dchiro-inositol in the polycystic ovary syndrome. N EnglJMed 1999;340:1314-20. (Pubitemid 29196593)
9. Genazzani AD, Lanzoni C, Ricchieri F, Jasonni VM. Myo-inositol administration positively affects hyperinsulinemia and hormonal parameters in overweight patients with polycystic ovary syndrome. Gynecol Endocrinol 2008;24:139-44. (Pubitemid 351365855)
10. Costello MF, Chapman M, Conway U. A systematic review and meta-analysis of randomized controlled trials on metformin co-administration during gonadotrophinovulation induction or IVF in women with polycystic ovary syndrome. Hum Reprod 2006;21:1387-99. (Pubitemid 44445013)
11. Zacchè MM, Caputo L, Filippis S, Zacchè G, Dindelli M, Ferrari A. Efficacy of myo-inositol in the treatment of cutaneous disorders in young women with polycystic ovary syndrome. Gynecol Endocrinol 2009;25:508-13.
12. Endo A. Monacolin K, a new hypocholesterolemic agent that specifically inhibits 3-hydroxy-3-methylglutaryl coenzyme A reductase. J Antibiot (Tokyo) 1980;33:334-6. (Pubitemid 11227437)
13. Sokalska A, Piotrowski PC, Rzepczynska IJ, Cress A, Duleba AJ. Statins inhibit growth of human thecainterstitial cells in PCOS and non-PCOS tissues independently of cholesterol availability. J Clin Endocrinol Metab 2010;95:5390-4.
14. Legro RS. Polycystic ovary syndrome and cardiovascular disease: a premature association? Endocrinol Rev 2003;24:302-12. (Pubitemid 36724372)
15. Diamanti-Kandarakis E, KandarakiE, Christakou C, Panidis D. The effect of pharmaceutical intervention on lipid profile in polycystic ovary syndrome. Obes Rev 2009;10:431-41.
16. Kazerooni T, Shojaei-Baghini A, Dehbashi S, Asadi N, Ghaffarpasand F, Kazerooni Y. Effects of metformin plus simvastatin on polycystic ovary syndrome: a prospective, randomized, double-bilnd, placebo-controlled study. Fertil Steril 2010;94:2208-13.
17. Feuerstein JS, Bjerke WS. Powdered red yeast rice and plant stanols and sterols to lower cholesterol. J Diet Suppl 2012;9:110-5.
18. Rotterdam E. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 2004;81:19-25.
19. Hosker JP, Matthews DR, Rudenski AS, Burnett MA, Darling P, Bown EG et al. Continuous infusion of glucose with model assessment: measurement of insulin resistance and β-cell function in man. Diabetologia 1985;28:401-11. (Pubitemid 15018831)
20. Ferriman D, Gallwey JD. Clinical assessment of body hair growth in women. Journal of Clinical Endocrinology 1961;21:1440-7.
21. Goodman N, Bledsoe M, Cobin R, Futterweit W, Goldzieher J, Petak S et al. American Association of Clinical Endocrinologists Hyperandrogenism Guidelines. Endocrine Practice 2001;7:120-34.
22. De Leo V, Di Sabatino A, Musacchio MC, Morgante G, Scolaro V, Cianci A et al. Effect of oral contraceptives on markers of hyperandrogenism and SHBG in women with polycystic ovary syndrome. Contraception 2010;2:276-80.
23. Lee CL, Pan TM. Development of Monascus fermentation technology for high hypolipidemic effect. Appl Microbiol Biotechnol 2012;4:1449-59.